Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Naomi N. H. Hunder"'
Autor:
Akshara Richhariya, Craig H. Moskowitz, Vijayveer Bonthapally, Jerzy Holowiecki, Patrick J. Stiff, Muneer H. Abidi, Elizabeth Thomas, John Radford, Scott D. Ramsey, Auayporn Nademanee, John W. Sweetenham, Yanyan Zhu, Tamas Masszi, Andy I. Chen, Simonetta Viviani, Naomi N. H. Hunder, Jan Walewski
Publikováno v:
British Journal of Haematology. 175:860-867
Summary Brentuximab vedotin (BV) significantly improved progression-free survival in a phase 3 study in patients with relapsed or refractory Hodgkin lymphoma (RR-HL) post-autologous-haematopoietic stem cell transplant (auto-HSCT); we report the impac
Autor:
Michael Pecsok, Patrick J. Stiff, Jerzy Holowiecki, Naomi N. H. Hunder, Auayporn Nademanee, Anna Sureda, Indra Purevjal, John W. Sweetenham, Muneer H. Abidi, Mayur Uttarwar
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 24(11)
The phase III AETHERA trial demonstrated the efficacy of brentuximab vedotin (BV) as consolidation therapy in patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression after autologous hematopoietic stem cell transplantatio
Autor:
Andy I. Chen, Eric L. Sievers, Patrick J. Stiff, Tamas Masszi, Andy Chi, Dirk Huebner, Jerzy Holowiecki, Angelo Michele Carella, Craig H. Moskowitz, Emily K. Larsen, Dzhelil Osmanov, Edward Agura, Veronika Bachanova, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Alessandro M. Gianni, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
The Lancet. 385:1853-1862
High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, mo
Publikováno v:
Journal of Clinical Pharmacology
Brentuximab vedotin, a CD30‐directed antibody‐drug conjugate (ADC), is approved for treating certain patients with CD30‐expressing hematologic malignancies. Its primary mechanism of action is the targeted delivery of a microtubule‐disrupting
Autor:
Dirk Huebner, Joseph M. Connors, Michelle A. Fanale, Anas Younes, Stephen M. Ansell, Megan M. O'Meara, Naomi N. H. Hunder, Steven I. Park
Publikováno v:
The Lancet. Oncology. 14(13)
Summary Background Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant cli
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Jerzy Holowiecki, Dzhelil Osmanov, Craig H. Moskowitz, John W. Sweetenham, Angelo Michele Carella, Alessandro Gianni, Patrick J. Stiff, Andy I. Chen, Jan Walewski, Yin Yang, Tamas Masszi, Dirk Huebner, Edward Agura, Auayporn Nadamanee, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(2):S115-S116
Autor:
Emily K. Larsen, Naomi N. H. Hunder, Jerzy Holowiecki, Simonetta Viviani, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Shih-Yuan Lee, Tamas Masszi, Veronika Bachanova, Muneer H. Abidi, Patrick J. Stiff, Craig H. Moskowitz, Andy I. Chen, Dirk Huebner
Publikováno v:
Journal of Clinical Oncology. 33:8519-8519
8519 Background: In the phase III, randomized, placebo-controlled AETHERA trial, PFS was significantly improved with brentuximab vedotin (BV) vs placebo (HR=0·57, P=0·001) in HL pts at risk of prog...
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Won Kim, John Radford, Jingyuan Wang, Anas Younes, Joseph M. Connors, Stephen M. Ansell, Tatyana Feldman, Dirk Huebner, Andrea Gallamini, Graham P. Collins, Naomi N. H. Hunder, Jessica A. Sachs, Nancy L. Bartlett, Kelly Brady, Jonathan W. Friedberg
Publikováno v:
Journal of Clinical Oncology. 32:TPS8613-TPS8613
TPS8612 Background: Brentuximab vedotin, a CD30-targeted antibody-drug conjugate, has conditional approval in Europe for relapsed/refractory (RR) CD30-positive HL following autologous stem cell tra...